non-hodgkin lymphoma

From the Field

Real-World Characteristics and Outcomes of Patients With Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Treated With First-Line Bendamustine + Rituximab

04/20/2022

Rouslan Kotchetkov, MD, PhD

David Susman

Erica DiMaria, MD

Lauren Gerard, MD

Derek Nay, MD

Dr Kotchetkov and colleagues assessed the pattern of B-R administration, efficacy and safety in adult patients with indolent non-Hodgkin lymphoma and mantle cell lymphoma with advanced disease and co-morbidities in the real-world setting.

Dr Kotchetkov and colleagues...

04/20/2022

Journal of Clinical Pathways

News

Reduced-Intensity Conditioning Regimens for Patients With NHL Undergoing Transplant

06/09/2020

Use of a more intense reduced-intensity conditioning and non-myeloablative conditioning (RIC-NMAC) regimen for allogeneic hematopoietic cell transplant (HCT) in patients with non-Hodgkin lymphoma should be considered...

Use of...

06/09/2020

Journal of Clinical Pathways

Research in Review

CAR-T Therapy Response Independent of Disease Factors in NHL

07/10/2017

JCP Editors

A recent clinical trial of a chimeric antigen receptor (CAR) T-cell therapy showed a significantly high response rate in treatment-resistant and relapsed aggressive non-Hodgkin lymphoma (NHL) independent of disease...

A...

07/10/2017

Journal of Clinical Pathways

Research in Review

High Response Rates With New Treatment for Aggressive B-Cell Lymphoma

06/13/2017

JCP Editors

In a recent trial, researchers determined complete response rates in patients with aggressive B-cell lymphomas after treatment with new a CAR T-cell product. ----- Related Content B-Cell ALL Disease Burden May...

In a...

06/13/2017

Journal of Clinical Pathways

Research in Review

Polypharmacy and Inappropriate Medications Negatively Impact Older Patients With NHL

06/07/2017

JCP Editors

Older patients with non-Hodgkin lymphoma (NHL) who take potentially inappropriate medications increase the risk of adverse survival impacts, according to research presented at the 2017 ASCO Annual Meeting (June 2-6,...

Older...

06/07/2017

Journal of Clinical Pathways

Research in Review

ASCT Deemed Safe and Effective for Older Patients With B-Cell Malignancies

05/25/2017

JCP Editors

Older patients with B-cell malignancies benefit from progression-free survival (PFS) and overall survival (OS) improvements after autologous stem cell transplantation (ASCT), according to research that will be...

Older...

05/25/2017

Journal of Clinical Pathways

Research in Review

Triple Combination Active in High-Risk B-Cell Malignancies

05/24/2017

JCP Editors

A combination of 3 pathway inhibitors is well tolerated with activity observed in heavily pre-treated and high-risk B-cell malignancies, according to research that will be presented at the ASCO Annual Meeting (June...

A...

05/24/2017

Journal of Clinical Pathways

Research in Review

CAR T-Cells Offer Biomarker for Objective Response in Non-Hodgkin Lymphoma

04/28/2017

JCP Editors

The ability of chimeric antigen receptor (CAR) T-cells to perform multiple functions is associated with improved outcomes for patients with advanced non-Hodgkin lymphoma, offering a biomarker for response, according...

The...

04/28/2017

Journal of Clinical Pathways

Research in Review

Serum Marker Helps Predict Response to CAR-T Therapy in Lymphoma

04/28/2017

JCP Editors

Patients with relapsed or refractory lymphoma who achieve durable remission after low-dose conditioning chemotherapy and anti-CD19 chimeric antigen receptor (CAR) T-cell therapy tend to have high serum levels of a...

...

04/28/2017

Journal of Clinical Pathways

Feature

Positioning CAR-T Therapy Into Clinical Pathways for Non-Hodgkin B-Cell Lymphoma and Beyond

03/23/2017

Chadi Nabhan, MD, MBA, FACP

Sandeep Parsad, PharmD, BCOP

Bruce A Feinberg, DO

Abstract: Enthusiasm for immunotherapy has spread throughout the oncology community in recent years, as therapies harnessing the body’s ability to fight cancers have offered the potential for remission and even cure...

...

03/23/2017

Journal of Clinical Pathways